Prenetics Global (PRE) Reports 480% Revenue Surge Driven by IM8 Brand Launch

Prenetics Global Limited (NASDAQ:PRE) is one of the most promising micro-cap stocks according to analysts. On February 18, Prenetics Global Limited reported financial results for 2025, headlined by a 480% year-over-year revenue surge to $92.4 million. This was fueled by the company’s flagship health and longevity brand, IM8, which reached an ARR of $120 million within just one year of its launch. The Q4 alone saw revenue reach of $36.6 million, a 55% increase over the previous quarter, reflecting the market traction of the brand co-founded by David Beckham.

The company completed a major strategic transformation by divesting non-core assets, including ACT Genomics, the Europa distribution business, and its stake in Insighta. These moves, including a $70 million cash sale of the Insighta stake to Tencent, have fortified the balance sheet with ~$171 million in adjusted liquidity and zero debt. Furthermore, Prenetics ceased all cryptocurrency purchases, maintaining a permanent holding of 510 BTC, as it pivots to become a pure-play leader in the consumer health and nutrition sector.

Looking ahead to 2026, Prenetics Global Limited (NASDAQ:PRE) reaffirmed its revenue guidance for IM8 at $180 to $200 million, aiming for an ARR of up to $300 million by year-end. A key driver for this anticipated growth is a shift toward quarterly subscription models, which has already increased the average order value to ~$233 in early 2026.

Prenetics Global Limited (NASDAQ:PRE) is a health sciences company that advances consumer health in Hong Kong, the US, and internationally. It sells health & wellness products under the IM8 brand name, and provides fulfillment & distribution services for sports nutrition products under the Europa brand.